Q1: What are the growth expectations from key brands, like Solosec and albuterol? How’re the pricing pressure and cost pressure affecting your plans in the US market?
Ans:
>Respiratory products, like albuterol, have become a growth driver for Lupin in the US
>Generic version of Brovana, another respiratory product, have about 45% share in the category
>Rest of the businesses in the US has been stable
Q2: What are the major product launches lined up for the US?
Ans:
>Expect to launch a couple of products in the US, like Spiriva, in the second half of this calendar year or the first quarter of FY23
>Expect to launch pegfilgrastim, Lupin’s first biosimilar in the US, in second half of FY23
>Hope to get the product approved following inspection of its Pune site
Q3: Are you planning to shift more production to India to offset growing cost pressures in the US?
Ans:
>Production of nasal spray products, developed in Somerset, US, moved to India
>Production of other first to file (FTF) products in the US, are being transferred to contract manufacturers in the US and India
>Exploring ways to improve cost position in products and risk mitigation
Q4: The India business is flat sequentially in Q3FY22. What is the outlook?
Ans:
>India business has grown 12% y-o-y, but sequentially it’s flat
>That’s because last year Lupin saw major growth in the respiratory products portfolio
>Launched Molnupiravir in the Covid products portfolio
>In India, more contribution will come from the diagnostic business
Q5: How are your China entry plans shaping up?
Ans:
>Announced partnership with Fancoo for CNS (Central Nervous System) products
>The products are awaiting approval, followed by the launch in China
>Working on respiratory products (developed for the US) for China, and simultaneously working out the entry strategy
Watch video
 "What are Lupin CEO Vinita Gupta's plans for growth in US & China?")
